Consensus $194.06M. The company said, “Treace is raising its full-year 2023 revenue guidance to $191 million to $197 million, which represents approximately 35% to 39% growth over the Company’s 2022 revenue. This compares to the prior full-year 2023 revenue guidance of $190 million to $196 million.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TMCI:
- Treace Announces Participation in the UBS Medtech, Tools and Genomics Summit 2023
- Treace to Report Second Quarter 2023 Financial Results on August 8, 2023
- Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer
- Treace Medical says Julie Dewey joins as Chief Communications and IR officer
- Treace Medical Completes Acquisition of Technology Enabling Patient Specific Instrumentation and Reports on Clinical Cases Using PSI with the Lapiplasty® System